Healthcare / Diagnostics & ResearchWarsaw
$123.20
-0.40 (-0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-31.7M · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$390M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.5%
↓Gross Margin
-3638.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-37.2%
FCF CAGR
—
FCF margin
-59498.0%
FCF / Net income
1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $100000.0 · net income $-46.4M · FCF $-59.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100000.00 | $100000.00 | $131000.00 | $516000.00 | $404000.00 |
| Net Income | $-46.4M | $-46.4M | $65.4M | $-18.8M | $318.5M |
| EBITDA | $-43.7M | $-43.7M | $87.1M | $-17.3M | $396.5M |
| EPS | -16.75 | -16.75 | 24.00 | -6.89 | 118.01 |
| Gross Margin | -3638.0% | -3638.0% | -901.5% | -265.9% | -115.8% |
| Operating Margin | -47282.0% | -47282.0% | -24799.2% | -5558.7% | -6246.0% |
| Net Margin | -46364.0% | -46364.0% | 49939.7% | -3640.5% | 78833.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 |
| Current Ratio | 13.06 | 13.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-59.5M | $-59.5M | $-31.7M | $-21.2M | $-29.5M |
| Returns | |||||
| ROE | -28.5% | -28.5% | 44.7% | -23.2% | 95.7% |
| Valuation | |||||
| P/E | — | — | 6.77 | — | 1.90 |
| EV/EBITDA | — | — | 3.62 | — | 0.70 |
| P/B | 2.40 | 2.40 | 3.02 | 7.41 | 1.82 |
| Growth & Yield | |||||
| Revenue Growth | -23.7% | -23.7% | -74.6% | 27.7% | — |
| EPS Growth | -169.8% | -169.8% | 448.3% | -105.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
n/dx → n/dx
EPS bridge
24.00 → -16.75
Residual
-19.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.